Anti-SARS-CoV-2 IgG levels in relation to disease severity of COVID-19

J Med Virol. 2022 Jan;94(1):380-383. doi: 10.1002/jmv.27274. Epub 2021 Aug 21.

Abstract

The durability of infection-induced severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) immunity has crucial implications for reinfection and vaccine effectiveness. However, the relationship between coronavirus disease 2019 (COVID-19) severity and long-term anti-SARS-CoV-2 immunoglobulin G (IgG) antibody level is poorly understood. Here, we measured the longevity of SARS-CoV-2-specific IgG antibodies in survivors who had recovered from COVID-19 1 year previously. In a cohort of 473 survivors with varying disease severity (asymptomatic, mild, moderate, or severe), we observed a positive correlation between virus-specific IgG antibody titers and COVID-19 severity. In particular, the highest virus-specific IgG antibody titers were observed in patients with severe COVID-19. By contrast, 74.4% of recovered asymptomatic carriers had negative anti-SARS-CoV-2 IgG test results, while many others had very low virus-specific IgG antibody titers. Our results demonstrate that SARS-CoV-2-specific IgG persistence and titer depend on COVID-19 severity.

Keywords: COVID-19; IgG; SARS-CoV-2; disease severity; serology.

Publication types

  • Observational Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Aged, 80 and over
  • Antibodies, Viral / blood*
  • Asymptomatic Infections
  • COVID-19 / pathology*
  • Child
  • Child, Preschool
  • Female
  • Humans
  • Immunoglobulin G / blood*
  • Infant
  • Infant, Newborn
  • Male
  • Middle Aged
  • SARS-CoV-2 / immunology*
  • Severity of Illness Index*
  • Time Factors
  • Young Adult

Substances

  • Antibodies, Viral
  • Immunoglobulin G